Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332

Watchlist Manager
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Logo
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
Watchlist
Price: 28.68 CNY 1.77% Market Closed
Market Cap: 46.1B CNY
Have any thoughts about
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd?
Write Note

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
Retained Earnings
ÂĄ24.5B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
19%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Retained Earnings
ÂĄ11.7B
CAGR 3-Years
36%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Retained Earnings
ÂĄ11.9B
CAGR 3-Years
22%
CAGR 5-Years
24%
CAGR 10-Years
26%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Retained Earnings
ÂĄ34.3B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Retained Earnings
ÂĄ20.1B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
10%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Retained Earnings
-ÂĄ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View

Market Cap
46.6B CNY
Industry
Pharmaceuticals

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, a leading player in China's pharmaceutical industry, stands out for its robust portfolio of products and a commitment to innovation. Founded in 1997 and headquartered in the bustling city of Guangzhou, the company has carved out a significant market presence through its diverse offerings, which include traditional Chinese medicines, chemical pharmaceuticals, and healthcare products. With a strong focus on research and development, Baiyunshan invests heavily in modernizing its production processes and expanding its product lineup, positioning itself well to capitalize on the growing demand for healthcare solutions in China and beyond. Its strategic partnerships and distribution capabilities further enhance its competitive edge, making it not just a manufacturer, but a trusted provider within the healthcare ecosystem. Investors looking at Guangzhou Baiyunshan should note the company’s impressive financial trajectory, characterized by consistent revenue growth and healthy profit margins. The pharmaceutical sector in China is poised for expansion due to an aging population and increasing health awareness, factors that bode well for Baiyunshan's future. The firm’s proactive approach to regulatory compliance and quality assurance has earned it a solid reputation with both consumers and industry stakeholders. As the company continues to enhance its research capabilities and expand its market reach, it represents a compelling opportunity for investors seeking exposure to the burgeoning Chinese pharmaceutical market. With a seasoned management team at the helm and a clear growth strategy, Guangzhou Baiyunshan is not just navigating the complexities of the pharmaceutical landscape; it is poised to thrive within it.

Intrinsic Value
36.24 CNY
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Retained Earnings?
Retained Earnings
24.5B CNY

Based on the financial report for Jun 30, 2024, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Retained Earnings amounts to 24.5B CNY.

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
19%

Over the last year, the Retained Earnings growth was 12%. The average annual Retained Earnings growth rates for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd have been 15% over the past three years , 15% over the past five years , and 19% over the past ten years .

Back to Top